newsfilter
← Latest News
GlobeNewswire·

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially value-creating